ID   GSK3A_RAT               Reviewed;         483 AA.
AC   P18265;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1990, sequence version 1.
DT   24-JUL-2024, entry version 195.
DE   RecName: Full=Glycogen synthase kinase-3 alpha;
DE            Short=GSK-3 alpha;
DE            EC=2.7.11.26;
DE   AltName: Full=Factor A;
DE            Short=FA;
DE   AltName: Full=Serine/threonine-protein kinase GSK3A;
DE            EC=2.7.11.1;
GN   Name=Gsk3a;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Brain;
RX   PubMed=2164470; DOI=10.1002/j.1460-2075.1990.tb07419.x;
RA   Woodgett J.R.;
RT   "Molecular cloning and expression of glycogen synthase kinase-3/factor A.";
RL   EMBO J. 9:2431-2438(1990).
RN   [2]
RP   PHOSPHORYLATION AT TYR-279.
RX   PubMed=8382613; DOI=10.1002/j.1460-2075.1993.tb05715.x;
RA   Hughes K., Nikolakaki E., Plyte S.E., Totty N.F., Woodgett J.R.;
RT   "Modulation of the glycogen synthase kinase-3 family by tyrosine
RT   phosphorylation.";
RL   EMBO J. 12:803-808(1993).
RN   [3]
RP   FUNCTION IN REGULATION OF PANCREATIC BETA-CELLS.
RX   PubMed=17242403; DOI=10.1074/jbc.m609637200;
RA   Mussmann R., Geese M., Harder F., Kegel S., Andag U., Lomow A., Burk U.,
RA   Onichtchouk D., Dohrmann C., Austen M.;
RT   "Inhibition of GSK3 promotes replication and survival of pancreatic beta
RT   cells.";
RL   J. Biol. Chem. 282:12030-12037(2007).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: Constitutively active protein kinase that acts as a negative
CC       regulator in the hormonal control of glucose homeostasis, Wnt signaling
CC       and regulation of transcription factors and microtubules, by
CC       phosphorylating and inactivating glycogen synthase (GYS1 or GYS2),
CC       CTNNB1/beta-catenin, APC and AXIN1. Requires primed phosphorylation of
CC       the majority of its substrates. Contributes to insulin regulation of
CC       glycogen synthesis by phosphorylating and inhibiting GYS1 activity and
CC       hence glycogen synthesis (By similarity). Regulates glycogen metabolism
CC       in liver, but not in muscle (By similarity). May also mediate the
CC       development of insulin resistance by regulating activation of
CC       transcription factors. In Wnt signaling, regulates the level and
CC       transcriptional activity of nuclear CTNNB1/beta-catenin. Facilitates
CC       amyloid precursor protein (APP) processing and the generation of APP-
CC       derived amyloid plaques found in Alzheimer disease (By similarity). May
CC       be involved in the regulation of replication in pancreatic beta-cells
CC       (PubMed:17242403). Is necessary for the establishment of neuronal
CC       polarity and axon outgrowth. Through phosphorylation of the anti-
CC       apoptotic protein MCL1, may control cell apoptosis in response to
CC       growth factors deprivation (By similarity). Acts as a regulator of
CC       autophagy by mediating phosphorylation of KAT5/TIP60 under starvation
CC       conditions, activating KAT5/TIP60 acetyltransferase activity and
CC       promoting acetylation of key autophagy regulators, such as ULK1 and
CC       RUBCNL/Pacer (By similarity). Negatively regulates extrinsic apoptotic
CC       signaling pathway via death domain receptors. Promotes the formation of
CC       an anti-apoptotic complex, made of DDX3X, BRIC2 and GSK3B, at death
CC       receptors, including TNFRSF10B. The anti-apoptotic function is most
CC       effective with weak apoptotic signals and can be overcome by stronger
CC       stimulation (By similarity). {ECO:0000250|UniProtKB:P49840,
CC       ECO:0000250|UniProtKB:P49841, ECO:0000250|UniProtKB:Q2NL51,
CC       ECO:0000269|PubMed:17242403}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[tau protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [tau protein]; Xref=Rhea:RHEA:12801, Rhea:RHEA-COMP:13701, Rhea:RHEA-
CC         COMP:13702, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.26;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[tau protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[tau protein]; Xref=Rhea:RHEA:53904, Rhea:RHEA-COMP:13703,
CC         Rhea:RHEA-COMP:13704, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.26;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000250|UniProtKB:Q2NL51};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- ACTIVITY REGULATION: Activated by phosphorylation at Tyr-279. In
CC       response to insulin, inhibited by phosphorylation at Ser-21 by
CC       PKB/AKT1; phosphorylation at this site causes a conformational change,
CC       preventing access of substrates to the active site. Inhibited by
CC       lithium (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Monomer. Interacts with ARRB2, AXIN1 and CTNNB1/beta-catenin
CC       (By similarity). Interacts with CTNND2 (By similarity). Interacts with
CC       LMBR1L (By similarity). Interacts with DDX3X (By similarity). Interacts
CC       with TNFRSF10B (By similarity). {ECO:0000250|UniProtKB:P49840}.
CC   -!- PTM: Phosphorylated by AKT1 at Ser-21: upon insulin-mediated signaling,
CC       the activated PKB/AKT1 protein kinase phosphorylates and deactivates
CC       GSK3A, resulting in the dephosphorylation and activation of GYS1.
CC       Activated by phosphorylation at Tyr-279 (By similarity). {ECO:0000250}.
CC   -!- MISCELLANEOUS: Simultaneous silencing of GSK3A and GSK3B by RNAi
CC       stimulates replication and promotes survival of INS-1E pancreatic beta
CC       cells. {ECO:0000305|PubMed:17242403}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr
CC       protein kinase family. GSK-3 subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X53427; CAA37518.1; -; mRNA.
DR   PIR; S14707; TVRTKA.
DR   RefSeq; NP_059040.1; NM_017344.1.
DR   AlphaFoldDB; P18265; -.
DR   SMR; P18265; -.
DR   BioGRID; 248424; 2.
DR   CORUM; P18265; -.
DR   IntAct; P18265; 3.
DR   STRING; 10116.ENSRNOP00000027677; -.
DR   ChEMBL; CHEMBL1075224; -.
DR   iPTMnet; P18265; -.
DR   PhosphoSitePlus; P18265; -.
DR   jPOST; P18265; -.
DR   PaxDb; 10116-ENSRNOP00000027677; -.
DR   DNASU; 50686; -.
DR   GeneID; 50686; -.
DR   KEGG; rno:50686; -.
DR   UCSC; RGD:620351; rat.
DR   AGR; RGD:620351; -.
DR   CTD; 2931; -.
DR   RGD; 620351; Gsk3a.
DR   VEuPathDB; HostDB:ENSRNOG00000020417; -.
DR   eggNOG; KOG0658; Eukaryota.
DR   InParanoid; P18265; -.
DR   OrthoDB; 2872909at2759; -.
DR   PhylomeDB; P18265; -.
DR   BRENDA; 2.7.11.26; 5301.
DR   PRO; PR:P18265; -.
DR   Proteomes; UP000002494; Chromosome 1.
DR   Bgee; ENSRNOG00000020417; Expressed in frontal cortex and 18 other cell types or tissues.
DR   ExpressionAtlas; P18265; baseline and differential.
DR   GO; GO:0030424; C:axon; IBA:GO_Central.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005874; C:microtubule; IDA:RGD.
DR   GO; GO:0005739; C:mitochondrion; IEA:GOC.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0034236; F:protein kinase A catalytic subunit binding; IPI:BHF-UCL.
DR   GO; GO:0004672; F:protein kinase activity; ISO:RGD.
DR   GO; GO:0019901; F:protein kinase binding; IPI:RGD.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0120283; F:protein serine/threonine kinase binding; IPI:BHF-UCL.
DR   GO; GO:0005102; F:signaling receptor binding; ISO:RGD.
DR   GO; GO:0050321; F:tau-protein kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0141068; P:autosome genomic imprinting; ISO:RGD.
DR   GO; GO:0003214; P:cardiac left ventricle morphogenesis; ISO:RGD.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0016477; P:cell migration; ISO:RGD.
DR   GO; GO:0071385; P:cellular response to glucocorticoid stimulus; ISO:RGD.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; ISO:RGD.
DR   GO; GO:0036016; P:cellular response to interleukin-3; ISS:UniProtKB.
DR   GO; GO:0071285; P:cellular response to lithium ion; ISO:RGD.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; ISO:RGD.
DR   GO; GO:0097191; P:extrinsic apoptotic signaling pathway; ISO:RGD.
DR   GO; GO:0097192; P:extrinsic apoptotic signaling pathway in absence of ligand; ISS:UniProtKB.
DR   GO; GO:0005977; P:glycogen metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; ISO:RGD.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IBA:GO_Central.
DR   GO; GO:0061052; P:negative regulation of cell growth involved in cardiac muscle cell development; ISO:RGD.
DR   GO; GO:2000171; P:negative regulation of dendrite development; IMP:RGD.
DR   GO; GO:0046325; P:negative regulation of glucose import; ISO:RGD.
DR   GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0032007; P:negative regulation of TOR signaling; ISO:RGD.
DR   GO; GO:0007399; P:nervous system development; IEA:UniProtKB-KW.
DR   GO; GO:0071879; P:positive regulation of adenylate cyclase-activating adrenergic receptor signaling pathway; ISO:RGD.
DR   GO; GO:0106071; P:positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway; ISO:RGD.
DR   GO; GO:1902004; P:positive regulation of amyloid-beta formation; ISO:RGD.
DR   GO; GO:0010508; P:positive regulation of autophagy; ISS:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISO:RGD.
DR   GO; GO:0045823; P:positive regulation of heart contraction; ISO:RGD.
DR   GO; GO:1901030; P:positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway; ISS:UniProtKB.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IMP:RGD.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; ISO:RGD.
DR   GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; ISO:RGD.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; ISO:RGD.
DR   GO; GO:1903955; P:positive regulation of protein targeting to mitochondrion; ISO:RGD.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; ISO:RGD.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; ISS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0070507; P:regulation of microtubule cytoskeleton organization; IBA:GO_Central.
DR   GO; GO:1901524; P:regulation of mitophagy; ISO:RGD.
DR   GO; GO:0010975; P:regulation of neuron projection development; IBA:GO_Central.
DR   GO; GO:0003073; P:regulation of systemic arterial blood pressure; ISO:RGD.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW.
DR   CDD; cd14137; STKc_GSK3; 1.
DR   Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1.
DR   InterPro; IPR050591; GSK-3.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR039192; STKc_GSK3.
DR   PANTHER; PTHR24057; GLYCOGEN SYNTHASE KINASE-3 ALPHA; 1.
DR   PANTHER; PTHR24057:SF14; GLYCOGEN SYNTHASE KINASE-3 ALPHA; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Acetylation; ATP-binding; Carbohydrate metabolism; Glycogen metabolism;
KW   Kinase; Neurogenesis; Nucleotide-binding; Phosphoprotein;
KW   Reference proteome; Serine/threonine-protein kinase;
KW   Signal transduction inhibitor; Transferase; Wnt signaling pathway.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000250|UniProtKB:P49840"
FT   CHAIN           2..483
FT                   /note="Glycogen synthase kinase-3 alpha"
FT                   /id="PRO_0000085979"
FT   DOMAIN          119..403
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..96
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          443..483
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        449..483
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        244
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         125..133
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         148
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0000250|UniProtKB:P49840"
FT   MOD_RES         2
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         21
FT                   /note="Phosphoserine; by PKB/AKT1"
FT                   /evidence="ECO:0000250|UniProtKB:Q2NL51"
FT   MOD_RES         72
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P49840"
FT   MOD_RES         77
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P49840"
FT   MOD_RES         97
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P49840"
FT   MOD_RES         279
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:8382613"
SQ   SEQUENCE   483 AA;  51027 MW;  A98DC1C5C7F7B716 CRC64;
     MSGGGPSGGG PGGSGRARTS SFAEPGGGGG GGGGGPGGSA SGPGGTGGGK ASVGAMGGGV
     GASSSGGGPS GSGGGGSGGP GAGTSFPPPG VKLGRDSGKV TTVVATLGQG PERSQEVAYT
     DIKVIGNGSF GVVYQARLAE TRELVAIKKV LQDKRFKNRE LQIMRKLDHC NIVRLRYFFY
     SSGEKKDELY LNLVLEYVPE TVYRVARHFT KAKLIIPIIY VKVYMYQLFR SLAYIHSQGV
     CHRDIKPQNL LVDPDTAVLK LCDFGSAKQL VRGEPNVSYI CSRYYRAPEL IFGATDYTSS
     IDVWSAGCVL AELLLGQPIF PGDSGVDQLV EIIKVLGTPT REQIREMNPN YTEFKFPQIK
     AHPWTKVFKS RTPPEAIALC SSLLEYTPSS RLSPLEACAH SFFDELRSLG TQLPNNRPLP
     PLFNFSPGEL SIQPSLNAIL IPPHLRSPSG PATLTSSSQA LTETQTGQDW QAPDATPTLT
     NSS
//
